Israel - English - Ministry of Health

rafa laboratories ltd - treprostinil as sodium salt - solution for inhalation - treprostinil as sodium salt 1.74 mg / 2.9 ml - treprostinil - treprostinil - treatment of pulmonary arterial hypertension in patients with nyha class iii symptoms, to increase walk distance.pulmonary hypertension associated with interstitial lung disease (ph-ild; who group 3) to improve exercise ability.

Israel - English - Ministry of Health

rafa laboratories ltd - oxycodone hydrochloride - tablets controlled release - oxycodone hydrochloride 5 mg - oxycodone - oxycodone - for the relief of moderate to severe chronic pain.

Israel - English - Ministry of Health

rafa laboratories ltd - oxycodone hydrochloride - tablets controlled release - oxycodone hydrochloride 5 mg - oxycodone - oxycodone - for the relief of moderate to severe chronic pain.

Israel - English - Ministry of Health

rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - pressurised suspention for inhalation - fluticasone propionate 0.05 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting β2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting β2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.flutiform 50mcg/5mcg inhaler is indicated in adults, adolescents and children aged 5 years and above.

Israel - English - Ministry of Health

rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - pressurised suspention for inhalation - fluticasone propionate 0.125 mg/dose; formoterol fumarate dihydrate 0.005 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting β2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting β2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.flutiform 125mcg/5mcg inhaler is indicated in adults and adolescents aged 12 years and above.

Israel - English - Ministry of Health

rafa laboratories ltd - fluticasone propionate; formoterol fumarate dihydrate - pressurised suspention for inhalation - fluticasone propionate 0.25 mg/dose; formoterol fumarate dihydrate 0.01 mg/dose - fluticasone - fluticasone - the regular treatment of asthma where use of a combination product (an inhaled corticosteroid and a long -acting β2 agonist) is appropriate:• for patients not adequately controlled with inhaled corticosteroids and ‘as required’ inhaled short -acting β2 agonist.• for patients already adequately controlled on both an inhaled corticosteroid and a long-acting β2 agonist.flutiform 250mcg/10mcg inhaler is indicated in adults only.

Israel - English - Ministry of Health

rafa laboratories ltd - roflumilast - film coated tablets - roflumilast 500 mcg - roflumilast - roflumilast - maintenance treatment of severe chronic obstructive pulmonary disease (copd) (fev1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment..

Israel - English - Ministry of Health

rafa laboratories ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 25 mg/vial - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

Israel - English - Ministry of Health

rafa laboratories ltd - bendamustine hydrochloride - powder for concentrate for solution for infusion - bendamustine hydrochloride 25 mg/vial - bendamustine - first-line treatment of chronic lymphocytic leukaemia (binet stage b or c) in patients for whom fludarabine combination chemotherapy is not appropriate.indolent non-hodgkin’s lymphomas as monotherapy in patients, who have progressed during or within 6 months following treatment with rituximab or a rituximab containing regimen.follicular non-hodgkin’s lymphoma as first line treatment in combination with rituximab.

Israel - English - Ministry of Health

rafa laboratories ltd - treprostinil as sodium salt - solution for inhalation - treprostinil as sodium salt 1.74 mg / 2.9 ml - treprostinil - treatment of pulmonary arterial hypertension in patients with nyha class iii symptoms, to increase walk distance.pulmonary hypertension associated with interstitial lung disease (ph-ild; who group 3) to improve exercise ability.